Compare KWR & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | RCUS |
|---|---|---|
| Founded | 1918 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 1994 | 2018 |
| Metric | KWR | RCUS |
|---|---|---|
| Price | $155.66 | $18.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $193.14 | $40.00 |
| AVG Volume (30 Days) | 98.2K | ★ 1.9M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.68 | N/A |
| Revenue | ★ $1,888,634,000.00 | $247,000,000.00 |
| Revenue This Year | $7.73 | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | $58.41 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $112.18 | $17.43 |
| 52 Week High | $183.01 | $31.74 |
| Indicator | KWR | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 44.16 | 28.06 |
| Support Level | $153.07 | N/A |
| Resistance Level | $163.12 | $24.38 |
| Average True Range (ATR) | 3.58 | 1.68 |
| MACD | -0.18 | -0.40 |
| Stochastic Oscillator | 35.45 | 16.87 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.